MeiraGTx Banner Image


  • Ticker MGTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
MeiraGTx Logo Image
  • 51-200 Employees
  • Based in New York City, New York
MeiraGTx is a clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with serious diseases. They currently have five programs in clinical development including three ocular indications, a salivary gland condition, and a Parkinson’s disease program. Their initial focus on diseases of the eye, salivary gland and central nervous systemMore is based on the significant unmet medical need coupled with the high potential gene therapy has to provide meaningful clinical benefit in these areas. With headquarters in New York and London, their global footprint provides them the opportunity to partner with leading institutions around the world, allowing them to deepen their understanding of diseases and their progression.
4.8 / 5.0 (134)

MeiraGTx reports have an aggregate usefulness score of 4.8 based on 134 reviews.


Most Recent Annual Report

MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

MeiraGTx Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!